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In this article we compare the efficacy of different pharmacological agents (ranitidine,
and omeprazole) to support phage transit from stomach to distal portions of the
gastrointestinal tract in rats. We show that a temporal modification of environment in
the animal stomach may protect Twort-like therapeutic antistaphylococcal phage A5/80
(from bacteriophage collection of the Hirszfeld Institute of Immunology and Experimental
Therapy PAS in Wroclaw, Poland) from the inactivation by gastric juice effectively enough
to enable a significant fraction of orally administered A5/80 to pass to the intestine.
Interestingly, we found that yogurt may be a relatively strong in enhancing phage transit.
Given the immunomodulating activities of phages our data may suggest that phages
and yogurt can act synergistically in mediating their probiotic activities and enhancing
the effectiveness of oral phage therapy. We also demonstrate that orally applied phages
of similar size, morphology, and sensitivity to acidic environment may differ in their
translocation into the bloodstream. This was evident in mice in which a therapeutic
staphylococcal phage A5/80 reached the blood upon oral administration combined with
antacid agent whilst T4 phage was not detected even when applied in 103 times higher
dose. Our findings also suggest that phage penetration from digestive tract to the blood
may be species-specific.
Keywords: bacteriophage, oral administration, gastric juice barrier, phage translocation, antacids, yogurt
INTRODUCTION
Growing antibiotic resistance of bacteria has rejuvenated the interest in using bacteriophages as
potential alternatives to antibiotics in the treatment of bacterial infections (Górski et al., 2016). Due
to their unique mechanism of antibacterial action phages are able to combat bacteria irrespectively
to bacterial antibiotic resistance profiles (Chan et al., 2013, 2016; Cao et al., 2015; Oduor et al., 2016;
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Ozkan et al., 2016). Phages use specific receptors at the surface
of bacterial cells to recognize targeted bacteria (Rakhuba et al.,
2010). Therefore their particular feature is a limited spectrum of
bacterial hosts. This ensures the targeting of infecting pathogen
and saving beneficial saprophytic flora – an important advantage
of phages over antibiotics in the fight with bacterial infections
(Abhilash et al., 2008). Despite of the progress in knowledge
on the potential application of phage therapy in medical and
veterinary practice many basic issues still need to be solved.
A crucial factor ensuring the effectiveness of phage therapy is the
bioavailability of phages at the infection site. With the exception
of external infections or infections in easy accessible body cavities
it requires the transit of phage from the site of application to the
site where the infecting bacteria reside.
The classification of the phages according to morphology
and nucleic acid by the International Committee on Taxonomy
of Viruses (ICTV) suggest that differences between them may
be extensive. Additionally, even phages belonging to the same
genera may differ significantly with respect to their sensitivity
to different environmental conditions (Jon´czyk et al., 2011).
However, there is a lack of complex studies which compare
bioavailability of different phages (Ackermann, 2003; Leiman
et al., 2003; Da˛browska et al., 2005). Detailed knowledge of
these processes (chance for the phage penetration to a site of
infection) have significant impact in determining therapeutic
recommendations for bacteriophage use. Phage bioavailability
after oral administration is one of them.
Oral drug application is one of the most convenient for
patients, and it was used for phage application by some
clinical centers conducting experimental phage therapy (Weber-
Da˛browska et al., 1987; Chanishvili, 2012; Mie˛dzybrodzki et al.,
2012; Sarker and Brüssow, 2016). It may be used both as a
local application for treatment of intestinal infections as well
as a systemic administration for treatment of diseases located
outside of the digestive tract (Zelasko et al., 2017). However,
the data confirming the possibility of the phage transit through
gastrointestinal mucosa in humans are scarce (Weber-Da˛browska
et al., 1987; Pagava et al., 2012).
Results of studies on animals concern single phages and
indicate that significant differences between phage ability to
penetrate the intestinal wall are possible (Da˛browska et al., 2005).
Geier et al. (1973) studied organ penetration of phage λ in mice.
They observed that after oral application of 2 × 1012 phage
particles the titer of phage in blood and organs was a few order
of magnitude lower than that after intramuscular, intravenous,
or intraperitoneal administration, and that the phage could be
detected for a shorter time (up to 30 h after p.o. administration
versus over 50 h after i.v. administration). Keller and Engley
(1958) showed that after oral administration of 4 × 109 pfu
of Bacillus megaterium 899a phage to mice the phage could be
detected in blood of most of the mice after 5 min and in urine
after 30 min. However, they could not confirm the presence of the
phage in blood in 14% of mice. Hildebrand and Wolochow (1962)
observed that orally administered T1 phage could penetrate into
the lymphatic system as it was shown for some bacteria and large
proteins but only in a small percentage of tested animals it was
able to penetrate into the blood.
Common sensitivity of phages to an acidic environment may
significantly reduce phage titers in stomach and the use of antacid
during oral phage therapy seems to be convincing solution of
this problem (Da˛browska et al., 2005; Jon´czyk et al., 2011). The
median gastric pH in fasting humans is 1.7 whereas in further
parts of alimentary tract it is over 6 (Dressman et al., 1990). This
forms physiological barrier to infection but it may also efficiently
inactivate certain phages (Jon´czyk et al., 2011). Therefore the
gastric juice barrier is a key factor which may influence phage
bioavailability in further parts of digestive tract as well as in blood
and body organs.
Oral phage administration is considered as a possible
therapeutic option in experimental phage therapy conducted
in patients of the Phage Therapy Unit of the HIIET PAS in
Wrocław. One of the most frequently used phages is broadly
polyvalent Staphylococcus aureus phage A5/80 (designated as
vB_SauM_A5/80 according to the recommended nomenclature;
Kropinski et al., 2009). Its clone of sequenced genome is known
as A5W. This tailed phage belongs to the Kayvirus genus of
the Spounavirinae subfamily of myoviruses that was recently
separated by ICTV from the previous Twortlikevirus genus
(Łobocka et al., 2012).1 In addition to A5/80 the Kayvirus
genus groups at least 11 phages of highly homologous genomic
sequences. A few of this phages, A5/80 among them, have been
successfully used in the treatment of staphylococcal infections in
humans and animals (Gill et al., 2006; Mie˛dzybrodzki et al., 2012;
Rose et al., 2014). The A5/80 virion consists of an icosahedral
capsid (71.5 nm in diameter which is packed with 146-bp dsDNA
molecule, and a 214.5 nm long, contractile tail. It was well
characterized at the level of genomic sequence (Łobocka et al.,
2012), but its bioavailability after oral administration have not
been systematically studied. Therefore, our aim was to verify the
effectiveness of different methods of neutralization or reducing
stomach juice acidity in overcoming the gastric juice barrier
by A5/80 bacteriophage and to test if the application of these
methods may improve the transfer of A5/80 through mucosa of
the gastrointestinal tract into blood in animal model. Escherichia
coli model phage T4 was used for comparative purposes in these
experiments. It is also a representative of Myoviridae family of
tailed phages (Leiman et al., 2003). Additionally, its total virion
length and head diameter (215 and 85 nm, respectively) are close
to those of A5/80.
MATERIALS AND METHODS
Animals
Experiments were performed on female Wistar rats (Wroclaw
Medical University) and DBA/1LacJ mice (animal facility of
the HIIET PAS under the license from the Jackson Laboratory,
USA) housed under standard conditions with food and water ad
libitum. All experiments were approved by the II Local Ethics
Committee in Wrocław, Poland. All oral applications in animals
were done into the stomach using a curved feeding needle (Kent
Scientific, Torrington, CT, USA).
1http://ictvonline.org/proposals/2015.005a-gB.A.v3.Kayvirus.pdf
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Phages
T4 phage was purchased from the American Type Culture
Collection (ATTC, Rockville, MD, USA). A5/80 phage was
obtained from the HIIET PAS therapeutic bacteriophage
collection.
Crude phage lysates were prepared according to the modified
method of S´lopek et al. (1983). Briefly, phages and the host
bacteria were added to peptone water and incubated at 37◦C until
complete lysis occurred (3–6 h). Phage A5/80 was incubated with
cells of Staphylococcus aureus 80, and phage T4 was incubated
with cells of E. coli B strain (standard bacterial hosts for the
propagation these phages). Then the suspensions were filtered
through a 0.22-µm Millipore filter. Both bacterial strains were
from the Polish Collection of Microorganisms (HIIET PAS,
Poland).
Testing the Influence of pH on the Phage
Survival
Phage-containing lysate (100 µl, 107 pfu/ml) was added to 900 µl
of saline solutions of different pH: 1.1, 2.0, 3.0, 4.0, 5.0, 6.0,
7.0, 7.4 (phosphate buffered saline – PBS), and 9.2. Phages were
incubated in solutions at 37◦C for 60 min. After incubation, each
phage suspension was serially 10-fold diluted with PBS for the
determination of phage titer.
Testing the Influence of Different Factors
Neutralizing or Reducing Stomach Juice
Acidity on the Phage Survival In vitro
Phage-containing lysate (0.5 ml, 107 pfu/ml) was added to
2.0 ml of dihydroxyaluminum sodium carbonate suspension
(Alugastrin R©, Polfa Łódz´ SA, Poland), ranitidine hydrochloride
syrup (Ranitydyna syrop, 75 mg/5 ml, Sanofi-Syntelabo Sp. z o.o.,
Poland), 3.2% fat milk (OSM Łowicz, Poland), natural yogurt
(Danone Sp. z o.o., Poland) or peptone water as control. Samples
were prepared in duplicate and incubated at 37◦C for 30 min.
After incubation, each phage suspension in buffer was serially 10-
fold diluted with peptone water for determination of the phage
titer. The change of phage activity was calculated as a percentage
of the mean phage titer in both samples of each tested factor
relative to the mean phage titer in control samples.
Protocol for Testing the Influence of
Different Agents on Overcoming the
Gastric Juice Barrier by the Phage
Phage-containing lysate (0.5 ml, 107 pfu/ml) was administered
orally to rats deprived of food for 24 h before beginning of the
experiment. Before phage administration, the rats were given:
- an oral dose of 1.0 ml of 68 mg/ml dihydroxyaluminum
sodium carbonate suspension (Alugastrin R©, Polfa Łódz´ SA,
Poland) 5–30 min. before phage administration,
- 5–75 mg/kg body weight oral dose of ranitidine hydrochloride
syrup (Ranitydyna syrop, 75 mg/5 ml, Sanofi-Syntelabo Sp. z
o.o., Poland) 2 h before phage administration,
- 2–50 mg/kg body weight of intraperitoneal ranitidine
(Zantac R©, for injections, 25 mg/ml, GlaxoSmithKline Export
Ltd, United Kingdom) 2 h before phage administration,
- 2.5–10 mg/kg body weight of intraperitoneal omeprazole
(Losec R©, for injections, 4 mg/ml, AstraZeneca AB, Sweden) 2 h
before phage administration,
- 2.0 ml of 3.2% fat milk per os (OSM Łowicz, Poland) 1
or10 min. before phage administration,
- 2.0 ml of natural yogurt (Danone Sp. z o.o., Poland) per os 1 or
10 min. before phage administration.
Control animals were given the phage lysates only. Rats were
sacrificed 30 min. after phage administration, and fragments of
duodenum, the middle section of the small intestine, and the
caecum were collected.
Testing the Influence of Alugastrin on
Gastrointestinal Transit of A5/80 Phage
in Rats
Rats were deprived of food for 24 h before beginning of the
experiment. They were administered 1.0 ml of Alugastrin per
os 1–60 min prior to A5/80 phage lysate application (dose:
0.5 ml, 108 pfu/ml). They were sacrificed 5–120 min after phage
administration and the intestinal contents were collected to
determine the phage titer.
Testing the Bioavailability of the Phages
after Administration to Rats
Rats were deprived of food for 24 h before beginning of the
experiment. In the first experiment A5/80 phage lysate (1.0 ml,
2 × 109 pfu) was applied orally 15 min after Alugastrin (1.0 ml
orally or intravenously) and the rats were sacrificed for collection
of blood and liver samples before experiment (control), and
1, 2, 4, and 18 h after. In the second experiment Alugastrin
was applied 10 min before phage administration (6 × 107 pfu
of A5/80 phage, and 4 × 107 pfu of T4 phage in 0.5 ml of
the phage lysate) and samples of blood, lymph (from cisterna
chyli), mesenteric and thoracic lymph nodes, and the middle
section of the small intestine were collected. To visualize the
lymph to enable its collection the animals received per os 1 ml
of rape oil 15 min before euthanasia according to Hildebrand
and Wolochow (1962). The animals were sacrificed 30 min after
phage administration and samples of blood, lymph, mesenteric
and thoracic lymph nodes, and small intestine (middle part) were
collected to determine the phage titer.
Testing the Influence of Alugastrin on
Bioavailability of the Phages after Oral
Administration to Mice
The mice were given 0.2 ml of the appropriate phage lysates.
Ten minutes before phage administration, they were given an
oral dose (0.2 ml) of Alugastrin. Control animals were given the
phage lysates only. After 1 h they were sacrificed and heparinized
whole blood samples and liver fragments were collected for
determination of the phage titer.
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Determination of the Phage Titers in
Samples
The phage titers both in in vitro as well as in vivo experiments
were determined in duplicate samples using the double-layer
agar method according to Adams (1959). Cells of E. coli B
strain and cells of S. aureus 80 strain that were used for the
T4 and A5/80 phage propagation were used as indicator strain,
respectively. Ten centimeter fragments of duodenum, the middle
section of the small intestine were rinsed out with 5 ml of PBS
for phage titration in diluted intestine contents. The content of
caecum was diluted in PBS in proportion of 100 mg/1 ml. Tissue
fragments (spleen, liver, lungs, kidney, brain, and lymph nodes)
were homogenized in PBS in proportion of 100 mg tissue per 1 ml
of PBS. Lymph was diluted 10–40 times with PBS for phage titer
determination. The phage titer in blood was assayed in undiluted
blood samples or in samples diluted with PBS when titer was high.
Statistical Analysis
Results are presented as mean phage titer (± standard error of the
mean, SE) in the analyzed sample. Differences between the study
groups were compared to the control using the non-parametric
Mann–Whitney U-test (in cases where the number of mice in
compared groups was 4 or higher). The differences between the
means were considered statistically significant at p< 0.05.
RESULTS
Both, A5/80 and T4, phages used in this study appeared to be
sensitive to inactivation at pH below 5, despite, that they differed
in the sensitivity to alkaline environment (Figure 1). Thus, one
can expect that they will be inactivated in a stomach, upon
exposure to gastric acid.
Commonly used pharmaceuticals that neutralize the
acidity of stomach juice or inhibit its production, when
administered orally are dihydroxyaluminum sodium carbonate
(Alugastrin), ranitidine hydrochloride (a H2-receptor antagonist)
or omeprazole (a proton pump inhibitor). Additionally, drinking
of milk or fermented milk products has been considered as
a natural stomach ulcer protective therapy (see e.g., Ippoliti
et al., 1976; Modlin, 1995; Elmståhl et al., 1998). Thus, we tested
whether certain of these various acidity decreasing agents will
not inactivate A5/80 or T4 bacteriophage in vitro, when added to
the suspensions of these phages (Table 1). Milk and yogurt had
a negligible effect on the titer of both phages. The influence of
Alugastrin on the titer of phage T4 was also negligible, but the
titer of phage A5/80 decreased to 40% after 30 min incubation
with Alugastrin. Ranitidine hydrochloride syrup decreased the
titer of both phages to about 2% or less.
We tested whether the aforementioned agents can increase the
ability of A5/80 phage to overcome the inactivating barrier of
stomach juice in vivo (Figure 2). Oral Alugastrin and ranitidine
(oral or parenteral) as well as parenteral omeprazole strongly
increased the ability of A5/80 phage to overcome gastric juice
barrier and pass to the further parts of the gastrointestinal tract in
rats. The effect of the highest applied oral versus intravenous dose
of ranitidine (75 mg/kg and 50 mg/kg, respectively) on phage titer
FIGURE 1 | Effect of acidity on phage survival. ∗Phosphate buffered
saline (pH 7.4) was used as control. The phages were incubated in buffers at
37◦C for 60 min.
attained in a small intestine was comparable but more phages
were detected in duodenum after i.v. application, although a 33%
lower dose of the H2 inhibitor was used. When lower doses of
ranitidine were applied we also observed higher phage transit
into the intestine in case of intravenous administration (the effect
of the lowest i.v. dose, 2 mg/kg, was almost 50 times higher
than effect of the lowest oral dose – 5 mg/ml). The activity of
omeprazole was much higher. When this proton pump inhibitor
was applied at a dose of 10 mg/kg it increased the phage titer in
a small intestine over six times more as compared to the effect
of 50 mg/kg of intravenous ranitidine. At a dose of 2.5 mg/kg
the effect of omeprazole was over 8 times stronger than i.v.
ranitidine at a dose of 2 or 10 mg/kg. When rats were pretreated
with 1.0 ml of Alugastrin, the highest phage titer was observed
in the small intestine when the phage was applied 5 min. after
the administration of Alugastrin and it was over two times
higher than the effect of oral ranitidine at a dose of 75 mg/kg.
Milk did not improve the intestinal transit of the A5/80 phage
significantly (Figure 2). Surprisingly, yogurt used just 1 min
before the application of the phage increased its titer in the small
intestine six times more than the medium dose of oral ranitidine
(25 mg/kg). Phage titers in the caecum were usually much lower
than those in a small intestine (data not shown).
Further experiments on the influence of Alugastrin on
bioavailability of A5/80 phage in gastrointestinal tract of rats
showed that the phage reached highest titer in the duodenum
and small intestine 30 min after its application (Figure 3), and
that the optimal time for administration of Alugastrin to increase
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TABLE 1 | Comparison of the bioavailability of A5/80 phage at different time points after its oral versus intravenous administration to rats.
Time since the phage
administration
Phage titer after oral administration [pfu/ml] Phage titer after intravenous administration [pfu/ml]
Blood Liver Blood Liver
n Mean n Mean n Mean n Mean
1 h 2 0 2 0 3 485† 2 419‡
2 h 3 0 2 0 1 50 – –
4 h 2 0 2 0 1 150 1 33
18 h 2 0 2 0 1 5 1 5
All animals received phage at dose of 2 × 109 pfu (in 1.0 ml of phage lysate). Alugastrin (1.0 ml) was applied 15 min before the phage administration. †, min.-max.
value: 405–555 pfu. ‡, min.-max. value: 373–465 pfu. No phage was detected neither in blood nor liver in a control group of two animals (non-treated with the phage).
N, number of tested animals.
the phage titer in these parts of gastrointestinal tract is its use
1–15 min before the phage administration (Figure 4).
We were not able to confirm the presence of active
A5/80 phage in blood samples collected during all the
above experiments (data not shown). Therefore we conducted
more detailed experiments on A5/80 bioavailability after oral
administration in rats (Tables 1, 2). Our experiment in which we
used a 40 times higher phage dose also did not confirm phage
penetration through rat intestinal mucosa into the bloodstream
(Table 1). Moreover we could not confirm that A5/80 phage was
able to penetrate into lymph (Table 2). The same results were
obtained for T4 phage. Unexpectedly, bioavailability studies done
in mice showed contrasting results (Table 3). They confirmed
that the A5/80 phage was able to penetrate into the bloodstream
of mice after its oral administration but it required concomitant
use of an antacid (the highest phage titer in blood was observed
60 min after the phage application). In contrast, T4 phage applied
at a dose 1000 times higher than A5/80 was detected in blood
only in trace amounts (even when the administration of phage
was preceded by the administration of Alugastrin).
DISCUSSION
We show here that a temporal modification of environment in
the animal stomach may protect therapeutic antistaphylococcal
phage A5/80 from the inactivation by gastric juice effectively
enough to enable a significant fraction of orally administered
A5/80 to pass to the intestine and even to a bloodstream.
Our results comparing the efficacy of different pharmacological
agents in protecting phage against inactivation by gastric juice
revealed that a proton pomp inhibitor, omeprazole was the
most efficient followed by a H2 receptor antagonist, ranitidine,
and dihydroxyaluminum sodium carbonate – an agent that is
traditionally used in phage treatment conducted at the Phage
Therapy Unit in Wroclaw (Mie˛dzybrodzki et al., 2012). The
data showing the applicability of omeprazole and ranitidine in
promoting phage transit to intestinal lumen may be relevant in
patients with gastrointestinal disorders where acid production
should be under strict control (e.g., peptic inflammation and
ulcer).
Although in vitro A5/80 phage is nearly completely inactivated
upon incubation with hyperosmotic ranitidine syrup or, to a
lesser extent, with alkaline Alugastrin (its pH is between 9.9
and 10.2 in a 1:25 suspension2), in vivo the administration
of ranitidine or Alugastrin to animals prior to the oral phage
administration significantly increased the number of phages that
could pass the stomach juice barrier retaining their activity.
A time period separating the administration of ranitidine
or Alugastrin from the administration of phage suspension
appeared to be an important parameter influencing the phage-
protective activity of each of these pharmaceuticals (Figure 2),
which should be taken into consideration in planning the
phage therapy regime whenever phage has to be administered
per os. To our surprise, yogurt turned out to be relatively
efficient in protecting phage from stomach juice, despite that
in the case of milk no clear effect was observed. This may
be associated with mildly acidic pH of Danone natural yogurt
(5.29 according to Çaglar et al., 2011) and with the yogurt
buffering activity (Kargul et al., 2007). In in vivo studies, the
ingestion of yogurt was shown to stabilize the gastric pH for
1 h at the level exceeding 3.5 (Martini et al., 1987). In contrast
to that whole milk as well as low-fat milk could cause the
increased gastric acid secretion, despite its transient buffering
activity (Ippoliti et al., 1976; Khanna and Abraham, 1990;
Marotta and Floch, 1991). Taken together, our data suggest
that yogurt when added to the current therapeutic protocols
of oral phage administration might improve the effectiveness
of therapy. This may also have important and therapeutic
implications related to suggested immunomodulating activities
of phages which may contribute to immunological hemostasis
in intestines referred to as probiotic like action of phages
(Górski and Weber-Da˛browska, 2005). Given the well-known
probiotic activities of yogurt in gut (reviewed by Adolfsson
et al., 2004) and the present data pointing to the so far
unknown ability of yogurt to promote phage survival and
gastrointestinal passage it suggest that phages and yogurt might
act synergistically in mediating their probiotic activities and
enhancing the effectiveness of oral phage therapy, for example
in the treatment of digestive tract infections. Taking under
consideration recent data presented by Przybylski et al. (2015)
on the anti-adenoviral activity of T4 phage one may speculate
that it might include not only bacterial but also viral infections.
2http://www.pharmacopeia.cn/v29240/usp29nf24s0_m26270.html
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FIGURE 2 | Influence of ranitidine, omeprazole, Alugastrin, yogurt, and milk on A5/80 phage ability to survive in the stomach and to pass into the
small intestine. Samples for phage titer determination were taken 30 min after oral administration of 0.5 ml of phage lysate (107 pfu/ml). Groups of animals differed
depending on a dose of stomach acid inhibitor (ranitidine or omeprazole), or time of the oral application of potential stomach juice neutralizer (1.0 ml of Alugastrin,
2.0 ml of yogurt, or 2.0 ml of milk) before phage administration. Control animals were given the phage lysates only. Shown is mean phage titer ± SE in analyzed
samples (n = 2–6).
Potential therapeutic value of this approach requires further
studies.
We also aimed to check if overcoming gastric juice barrier
by A5/80 phage enables its systemic detection upon oral
administration. Because we were not able to detect orally
administered A5/80 as well as T4 phage (used here for
comparative purposes) in the bloodstream of rats, even when the
administration of these phages was combined with antacid agent
we performed experiments on mice. Unexpectedly, results for
A5/80 and T4 were completely different, despite the similarities
in the size and morphology of these phages and their similar
sensitivity to acidic environment in vitro. This was evident
where a staphylococcal A5/80 phage reached the blood upon
oral administration combined with gastric acid neutralization
whilst T4 phage did not, even though it was applied in 1000-
times higher dose. At least a few phage features and non-phage
dependent factors could possibly cause this difference. The first
one is phage susceptibility to digestive enzymes and bile salts
(Ma et al., 2008). However, a sensitivity to these digestive tract
components is unlikely in the case of T4 because T4 was able
to survive in the small intestine of rats even better than A5/80
(Table 2). The second one is a possible phage interaction with
bacteria of gut microbiome of tested animals. The A5/80 or
T4 adsorption to dead bacteria or to the remnants of their
envelopes containing phage receptors will inevitably lead to the
irreversible phage inactivation. The adsorption to living bacteria
can have several outcomes, with the exception of lysogeny and
transduction, as A5/80 and T4 are obligatorily virulent and non-
transducing phages (Łobocka et al., 2012, 2014; and references
therein). It can be productive leading to a temporal decrease and
later to the increase in phage titer, when the progeny of adsorbed
phages is released from the infected bacteria. Alternatively, it
can be non-productive due to the inability of infected cell
to support phage development, to the degradation of injected
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FIGURE 3 | Influence of Alugastrin on A5/80 phage intestinal transit. 1.0 ml of antacid was given to animals 15 min before administration of the
phage. Samples of the intestinal contents were collected for phage titer determination at different time points (5–120 min) after oral administration of 0.5 ml of phage
lysate (108 pfu/ml). Shown is mean phage titer ± SE in analyzed samples (n = 1–4).
FIGURE 4 | Intestinal transit of A5/80 phage applied orally at different time points (1–60 min) after oral administration of an antacid (1 ml of
Alugastrin). Samples of the intestinal contents were collected for phage titer determination 30 min after administration of 0.5 ml of phage lysate (108 pfu/ml). Shown
is mean phage titer ± SE in analyzed samples (n = 3–4).
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TABLE 2 | Orally administered A5/80 and T4 phage penetration into blood, lymph, mesenteric and thoracic lymph nodes, and small intestine (middle part)
in rats.
Phage/sample Phage titer in analyzed samples [pfu/ml]
Control Phage Phage+Alugastrin
n Mean SE n Mean SE n Mean SE
A5/80 phage
Blood 4 0 0 4 0 0 4 0 0
Lymph 4 0 0 4 0 0 4 0 0
Mesenteric lymph nodes 4 0 0 4 0 0 4 0 0
Thoracic lymph nodes 4 0 0 4 0 0 4 0 0
Small intestine 4 0 0 4 37 37 4 444 271
T4 phage
Blood 3 0 0 3 0 0 3 0 0
Lymph 2 0 0 2 0 0 1 0 –
Mesenteric lymph nodes 3 0 0 3 0 0 3 6 5
Thoracic lymph nodes 2 0 0 3 0 0 3 5 3
Small intestine 3 12 12 3 1 348 1 116 3 14 667 12 719
Alugastrin was applied 10 min before the phage administration. Animals were euthanized 30 min after application of the phage preparation (0.5 ml per animal). The phage
dose was: 6 × 107 pfu of A5/80 phage, and 4 × 107 pfu of T4 phage. 15 min before termination of the experiment all rats (including the control group) received per os
1 ml of rape oil to visualize the lymph. SE, standard error of the mean; n, number of tested animals.
TABLE 3 | Bioavailability of A5/80 and T4 phages in blood and liver after their oral administration to mice.
Phage Dose [pfu] Group Time from the phage application Phage titer in samples [pfu/ml]
Blood Liver
n Mean SE n Mean SE
A5/80 5 × 106 Control 15 min 5 217 212 5 20 20
30 min 6 1 1 6 0 0
60 min 4 17 17 4 2 2
120 min 4 11 11 4 1 1
180 min 4 21 19 4 0 0
Alugastrin 15 min 4 108 106 4 3 1
30 min 9 806 482 9 155∗ 70
60 min 7 2 783∗ 936 7 637∗ 463
120 min 4 363 363 4 33 32
180 min 4 28 28 4 10 6
T4 5 × 106 Control 60 min 3 10 8 3 0 0
Alugastrin 60 min 3 3∗∗ 1 3 0∗∗ 0
7 × 109 Control 60 min 3 1 1 3 3 1
Alugastrin 60 min 3 18∗∗ 15 3 66 63
Alugastrin (0.2 ml) was applied 10 min before the phage administration. Control group received only 0.2 ml of appropriate phage lysate. SE, standard error of the mean;
n, number of tested animals. ∗p < 0.05 when compared to control group. ∗∗p < 0.05 when compared to A5/80 phage and Alugastrin treated group tested after 60 min.
phage DNA by bacterial restriction enzymes or the CRISPR-Cas
immunity system, to the abortive infection mechanisms, or to the
bacterial toxin-antitoxin system activation (reviewed by Labrie
et al., 2010). In our experiments the decrease of A5/80 or T4
titer upon 15 and 45 min. incubation of each of these phages
with the content of mice or rat intestine, did not exceed one
order of magnitude (Supplementary Tables 4–6). Moreover, in
the case of certain mice we observed an increase in T4 phage
titer 45 min. after the phage incubation with the intestine content.
These changes are indicative of both the possibility of inactivation
of some A5/80 or T4 phages in the intestine as well as the
possibility of productive infection of some intestinal bacteria by
T4. However, in our opinion they are too small to explain the
difference in murine blood titers of A5/80 and T4 applied in
103 higher dose than A5/80. We were able to detect bacterial
strains susceptible to both phages in the rat intestines (detailed
data presented in Supplementary Materials), but were not able to
detect them in the intestine of mice. Conceivably, in mice they do
not predominate among enterobacteria of the gut microbiome.
Another reason of the absence of T4 in blood could be its direct
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inactivation in blood – for example by the presence of anti-T4
phage or cross-reacting antibodies (Da˛browska et al., 2014). Our
control experiments showed that 60 min incubation of T4 phage
in full blood samples of mice (at 37◦C) did not decreased its
activity, and that the phage incubation with rat or murine serum
resulted only in less than 25% drop in its titer (for details please
see Supplementary Tables 2, 3). Therefore, we hypothesize that
differences in the ability of A5/80 and T4 to penetrate from the
intestine to blood in our experiments might result from different
interactions of these phages with intestinal mucus layer and/or
intestinal mucosa.
T4-like phages are natural components of mammalian gut
as indicated by several cases of their isolation from stool
samples (see e.g., Furuse et al., 1983; Kutter et al., 1995;
Chibani-Chennoufi et al., 2004). The digestive tract is a natural
reservoir of their host bacteria. Evolutionary, these phages could
hardly benefit from the passage from the intestinal lumen to
a bloodstream. Instead one may expect that they developed
strategies to ensure their retention in the digestive tract. The T4
capsid-exposed protein Hoc was shown previously to interact
with mammalian organisms (Da˛browska et al., 2006, 2007) and
to bind to mucin glycoproteins (Barr et al., 2013). Recently
Barr et al. (2015) demonstrated that the T4 adherence to mucus
and Hoc interaction with mucin glycoproteins are responsible
for the subdiffusive motion of T4 in the mucus, as compared
to the diffusive motion of the T41hoc phage. As a result of
the subdiffusive motion wild-type T4 could reduce the bacterial
colonization of the epithelium 4,000-fold more efficiently than
its 1hoc mutant. Possibly, T4 is trapped in the intestinal mucus
and thus cannot penetrate further layers of the intestinal barrier.
Studies are in progress to find out whether the hoc gene deletion
will influence the systemic bioavailability of orally administered
T4 phage.
In the intestine, a physical barrier between the intestinal
lumen, the lamina propria and the mucosal-associated lymphoid
tissue is the intestinal epithelium. It is formed by a single layer
of cells and mostly contain enterocytes (absorptive epithelial
cells), microfold (M) cells (non-absorptive epithelial cells) and
goblet cells scattered among them. Mucus secreted by the goblet
cells spatially compartmentalizes the bacteria to the lumen
(Johansson et al., 2011). The paracellular flux through this
layer is limited by tight junctions that form interconnections
between the most apical parts of the epithelial cells. The size
of particles that can penetrate through tight junctions does not
exceed 10 nm (Fihn et al., 2000; Shen et al., 2011), which is too
small for the passage of A5/80 and T4 phage. An alternative
is a transenterocytic pathway or the M-cell-mediated pathway.
The former occurs by endocytosis through the apical enterocyte
membrane, followed by intracellular trafficking and exocytosis
through the basolateral membrane (reviewed by Yu et al., 2016).
However, the endocytosis of A5/80 by enterocytes might require
specific receptors as it was shown for certain pathogens that are
translocated via this pathway across the intact intestinal barrier.
Thus, the more likely way of A5/80 passage through the intestinal
barrier is the M-cell-mediated pathway. M cells are specialized
in antigen sampling, have a strong transcytotic capacity, and can
transport many bacteria and viruses, as well as other antigens
from the intestinal lumen to the underlying lymphoid tissues
to induce immune responses (Kyd and Cripps, 2008; Gonzalez-
Hernandez et al., 2014; Chamcha et al., 2015). Limitations of
this pathway are the low proportion of M cells (1%) in the
intestinal epithelium, as compared to other cells, and a possibility
of capturing the transported bacteria or viruses by macrophages
and dendritic cells (Yu et al., 2016).
Our results demonstrating weak, if any, T4 phage ability to
translocate through the intestinal mucosa are in agreement with
the results of Bruttin and Brüssow (2005) who were not able to
detect T4 phages in blood after their oral application to human
volunteers. The possibility of passage of orally administered T4-
like coliphages (isolated from stool samples of pediatric patients
with diarrhea and from environmental water samples) through
the intestinal tract of mice was demonstrated previously, but
in all these cases the presence of phages was restricted to a
gut lumen (Chibani-Chennoufi et al., 2004). In a limited study
using three horses, Letarova et al. (2012) also was not able to
detect fecal phages in blood although they were detected in faces
of animals even over 107 pfu/ml. Only Majewska et al. (2015)
reported detection of T4 phage in blood after its oral application
to mice. In our opinion it could be facilitated by a long-term
phage application (the experiment lasted for 100 days), a high
phage dose (4 × 1010 pfu/ml of drinking water), as well as by a
repeated collection of blood samples which could cause stress and
hence could also influence the permeability of the gastrointestinal
tract mucosa.
The recent data by Thannesberger et al. (2017) indicate that
phages may be detected in large quantities in human urine
which suggest that they could translocate from the intestinal
tract and migrate to other tissues which has a clear clinical
significance and relation to our current data presented in this
article. The data of Weber-Da˛browska et al. (1987) and Pagava
et al. (2012) suggesting that in patients on oral phage therapy
phages may translocate from intestines to peripheral blood, as
well as our data, confirm the value of oral phage application as
efficient means of delivering phages to sites of infections and
thereby successful therapy in patients with bacterial infections,
as described earlier (Mie˛dzybrodzki et al., 2012). Interspecies
differences in phage translocation reported in this article suggest
that this phenomenon should be studied in detail in human
clinical trials.
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